|Dr. Steven J. Mento Ph.D.||Exec. Chairman, Interim Pres & CEO||335.4k||N/A||1952|
|Ms. Susan A. Knudson||Exec. VP, CFO, Chief Compliance Officer & Corp. Sec.||385.25k||N/A||1964|
|Dr. Gail K. Naughton Ph.D.||Founder & Scientific Advisor||N/A||N/A||1956|
|Mr. Stephen Hill Jr.||VP & Controller||N/A||N/A||N/A|
|Mr. Thomas L. Hubka||Director of Bus. Operations & Corp. Sec.||N/A||N/A||1987|
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Histogen Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.